Characterization of the T-cell response in a patient with phenindione hypersensitivity

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 3, 2005, Pages 1058-1065

  Naisbitt, Dean J ^a   Farrell, John ^a   Chamberlain, Peter J ^a   Hopkins, Josephine E ^a   Berry, Neil G ^a   Pirmohamed, Munir ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 INDANDIONE DERIVATIVE; 2 PHENYLINDENE; 3 IMINOISOINDOLINE; ANTICOAGULANT AGENT; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; INDAN DERIVATIVE; INDANONE DERIVATIVE; INTERLEUKIN 5; PHENINDIONE; PHENYLINDOLE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ANTIGEN PRESENTATION; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; COMPUTER MODEL; CYTOKINE RELEASE; DRUG HYPERSENSITIVITY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION TEST; PRIORITY JOURNAL; SKIN ALLERGY; T LYMPHOCYTE ACTIVATION;

DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-5; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MODELS, MOLECULAR; PHENINDIONE; T-LYMPHOCYTES;

EID: 19444368749     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.083758     Document Type: Article

References (39)

1. Allen JN, Liao Z, Wewers MD, Altenberger EA, Moore SA, and Allen ED (1996) Detection of IL-5 and IL-1 receptor antagonist in bronchoalveolar lavage fluid in acute eosinophilic pneumonia. J Allergy Clin Immunol 97:1366-1374.
2. Brander C, Mauri-Hellweg D, Bettens F, Rolli H, Goldman M, and Pichler WJ (1995) Heterogeneous T-cell responses to beta-lactam-modified self structures are observed in penicillin-allergic individuals. J Immunol 155:2670-2678.
3. Bundgaard H (1975) Identification and quantitation of a 3-benzylidenephthalide contaminant of phenindione tablets and its characterization as a potentially immunogenic substance. Acta Pharm Suec 12:333-348.
4. Burkhart C, von Greyerz S, Depta JP, Naisbitt DJ, Britschgi M, Park KB, and Pichler WJ (2001) Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Br J Pharmacol 132:623-630.
5. Clark M, Cramer RD, and Van Opdenbosh N (1989) Validation of the general-purpose TRIPOS 5.2 force-field. J Comput Chem 10:982-1012.
6. Depta JP, Altznauer F, Gamerdinger K, Burkhart C, Weltzien HU, and Pichler WJ (2004) Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. J Allergy Clin Immunol 113:519-527.
7. De Vries J, Verboom CN, De Neef JH, Groot EJ, and Nauta WT (1977) High pressure liquid chromatographic separation of 2-phenyl-1,3-indandione and its oxidation and rearrangement products. J Chromatogr 152:557-559.
8. Farrell J, Naisbitt DJ, Drummond NS, Depta JP, Vilar FJ, Pirmohamed M, and Park BK (2003) Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans. J Pharmacol Exp Ther 306:229-237.
9. Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, and Descamps V (2003) A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 149:1018-1022.
10. Gasteiger J and Marsili M (1981) Prediction of proton magnetic-resonance shifts - the dependence on hydrogen charges obtained by iterative partial equalization of orbital electronegativity. Organ Magn Reson 15:353-360.
11. Gell PGH and Coombs RRA (1963) The classification of allergic reactions underlying disease, in Clinical Aspects of Immunology (Coombs RRA and Gell PGH eds) pp 317-337, Blackwell Science, Oxford, UK.
12. Hashizume H, Takigawa M, and Tokura Y (2002) Characterization of drug-specific T cells in phenobarbital-induced eruption. J Immunol 168:5359-5368.
13. Kuechler PC, Britschgi M, Schmid S, Hari Y, Grabscheid B, and Pichler WJ (2004) Cytotoxic mechanisms in different forms of T-cell-mediated drug allergies. Allergy 59:613-622.
14. Landsteiner K and Jacobs J (1935) Studies on the sensitization of animals with simple chemical compounds. J Exp Med 61:643-656.
15. McMenamin RA, Davies LM, and Craswell PW (1976) Drug induced interstitial nephritis, hepatitis and exfoliative dermatitis. Aust NZ J Med 6:583-587.
16. Mohamed SD (1965) Sensitivity reaction to phenindione with urticaria, hepatitis and pancytopenia. Br Med J 5476:1475-1476.
17. Naisbitt DJ (2004) Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 194:179-196.
18. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, and Park BK (2003a) Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype and cytokine profile of drug-specific T cell clones. Mol Pharmacol 63:732-741.
19. Naisbitt DJ, Farreli J, Gordon SF, Maggs JL, Burkhart C, Pichler WJ, Pirmohamed M, and Park BK (2002) Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 62:628-637.
20. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, Gibney CA, Chadwick DW, Pichler WJ, Pirmohamed M, and Park BK (2003b) Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 111:1393-1403.
21. Naisbitt DJ, Gordon SF, Pirmohamed M, Burkhart C, Cribb AE, Pichler WJ, and Park BK (2001) Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 133:295-305.
22. Nyburg SC (1974) Some uses of a best molecular fit routine. Acta Crystallogr Sec B 30:251-253.
23. Nyfeler B and Pichler WJ (1997) The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 27:175-181.
24. Pichler WJ (2003) Delayed drug hypersensitivity reactions. Ann Intern Med 139: 683-993.
25. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, Kuechler P, and Naisbitt D (2002) Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 3:229-238.
26. Pipkin JD and Stella VJ (1982) Tautomerism of phenindione, 2-phenyl-1,3-indandione, in dipolar aprotic hydrocarbon solvent mixtures. J Am Chem Soc 104:672-680.
27. Potier JC, Bories H, Foucault JP, and Olivier J (1975) Letter: a new case of severe intolerance to phenindione. Value of the lymphoblastic transformation test. Nouv Presse Med 4:2041.
28. Sachs B, Erdmann S, Malte Baron J, Neis M, al Masaoudi T, and Merk HF (2002) Determination of interleukin-5 secretion from drug-specific activated ex vivo peripheral blood mononuclear cells as a test system for the in vitro detection of drug sensitization. Clin Exp Allergy 32:736-744.
29. Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt DJ, Pirmohamed M, Park BK, and Pichler WJ (2000) Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 164:6647-6654.
30. Schnyder B, Frutig K, Mauri-Hellweg D, Limat A, Yawalkar N, and Pichler WJ (1998) T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazole-induced skin reaction. Clin Exp Allergy 28:1412-1417.
31. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, and Pichler WJ (1997) Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Investig 100:136-141.
32. Schulert AR and Weiner M (1954) The physiologic disposition of phenylindanedione in man. J Pharmacol Exp Ther 110:451-457.
33. Spyropoulos AC, Hayth KA, and Jenkins P (2003) Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy 23:533-536.
34. von Greyerz S, Bultemann G, Schnyder K, Burkhart C, Lotti B, Hari Y, and Pichler WJ (2001) Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. Int Immunol 13:877-885.
35. Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, and Pichler WJ (2000a) Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 30:847-855.
36. Yawalkar N and Pichler WJ (2001) Pathogenesis of drug-induced exanthema. Int Arch Allergy Immunol 124:336-338.
37. Yawalkar N, Shrikhande M, Hari Y, Nievergelt H, Braathen LR, and Pichler WJ (2000b) Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 106: 1171-1176.
38. Zanni MP, von Greyerz S, Hari Y, Schnyder B, and Pichler WJ (1999) Recognition of local anesthetics by alphabeta+ T cells. J Investig Dermatol 112:197-204.
39. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, Hari Y, Valitutti S, and Pichler WJ (1998) HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Investig 102:1591-1598.